Volume 1 (3). June 2013.

GLIOMAS.ORG NEWSLETTER
_______________________________________________________________________________________________________
GLIOMAS.ORG NEWSLETTERS is a short electronic newsletter periodically released by e-mail as a PDF file to subscribers who want to keep updated on the latest advances on glioma research including but not limited to:
DRUGS & CHEMOTHERAPY NEURORADIOLOGY NEUROIMAGING NEUROSURGERY NEUROPHARMACOLOGY NANOMEDICINE GLIOMA BIOLOGY CLINICAL STUDIES related to the diagnosis, treatment and prognosis of glioma patients. GLIOMAS.ORG. An International Consortium

Mission: To speed research in gliomas.

ACTIVITIES: Research Education Communication Lates updates Patient support Conference Meetings

Each issue of GLIOMAS NEWSLETTERS is the result of a broad screening of the literature in free (e.g. pubmed) or subscription based (e.g. ISI) databases and journals. Interaction with the industry and academic institutions guarantee the early release of relevant information for patients and professionals. The highlights of important studies are briefly summarized in a friendly medical language. Each summary is convenient cited (Reference) at the bottom of the summary to allow anyone interested to quickly find the original source.
www.gliomas.org

New issues of GLIOMAS.ORG NEWSLETTERS are released to subscribers twice a month by e-mail. Old issues are posted online in www.gliomas.org/nl and can be freely distributed by any media. We encourage professionals, clinics and other institutions to print and distribute our newsletter to their staff and patients.
IMAGES IN GLIOMAS RESEARCH

Electron micrographs of adherent U87-MG cells treated with or without coibamide A (20 nM). Ultrastructure of representative control (panel a) and treated U87-MG cells at 16 (panel b) and 48 h (panels c to e). Electron micrographs of adherent U87-MG cells treated with or without coibamide A (20 nM). Ultrastructure of representative control (panel a) and treated U87-MG cells at 16 (panel b) and 48 h (panels c). FROM Hau AM, Greenwood JA, Lhr CV, Serrill JD, Proteau PJ, Ganley IG, McPhail KL, Ishmael JE. Coibamide A Induces mTOR-Independent Autophagy and Cell Death in Human Glioblastoma Cells. PLoS One. 2013 Jun 6;8(6):e65250. doi: 10.1371/journal.pone.0065250. _____________________________________________________________________________________________________________________________ Volume 1 (3), June 2013. www.gliomas.org

GLIOMAS.ORG NEWSLETTERS TRADITIONAL CHINESE MEDICINE Cryptotanshinone inhibits human glioma cell proliferation

Cryptotanshinone (CTS), the main bioactive compound from the root of Salvia miltiorrhiza Bunge, which is often used as Chinese herbal medicine in cancer. CTS significantly suppresses glioma cell proliferation of human glioma cell lines (T98G and U87). Its mechanism may be related to the inhibition of STAT3 signaling.
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, Peng J, You Y, Zhang X, Shen X. Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem. 2013 Jun 6. [Epub ahead of print]

In addition, the extent of resection when is objectively assessed by measuring pre- and postoperative tumor volumes, surgery has a strong favorable impact on survival, especially if resection is complete on postoperative MRI.
Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, Pallud J, Peruzzi P, Baron MH, Kujas M, Guyotat J, Guillevin R, Frenay M, Taillibert S, Colin P, Rigau V, Vandenbos F, Pinelli C, Duffau H; French Rseau d'tude des Gliomes (REG). Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases. J Neurosurg. 2013 Jun;118(6):1157-68. doi: 10.3171/2013.1.JNS121.

GLIOMAGENESIS Variants in telomerase-related genes are associated with an older age at diagnosis

Four cytokines predicts the prognosis of patients with malignant gliomas

Single nucleotide polymorphisms (SNPs) in genes implicated as risk factors for gliomas are associated with early age at diagnosis, However, variation in 2 genes (TERT, RTEL1) involved in telomerase structure/function was associated with older age at diagnosis. It seems that mechanisms of telomere maintenance, e.g. telomerase-related genes telomerase-independent mechanisms (ie, alternative lengthening of telomeres), may be the underlying factor.
Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, Sicotte H, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro Oncol. 2013 Jun 3. [Epub ahead of print]. PMID: 23733245 [PubMed -

From a study of 120 cytokines and growth factors four were associated with poor prognosis (IL-15, MCP-1, GDNF, IL1R4/ST2), and six were associated with good prognosis (IGFBP6, MIP-1, ICAM-3, IL-7, MIP-3, and sgp130). Moreover, a 4cytokine panel composed of IL-7, IL1R4/ST2, sgp130 and MCP-1 showed significant correlation with overall survival . The authors suggest that this panel of four cytokines: IL-7, IL1R4/ST2, sgp130, and MCP-1 can serve as a prognostic marker for patients with malignant gliomas.
Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang J, Li G, Song SW, Qiu X, Wang Y, Jiang T. A panel of four cytokines predicts the prognosis of patients with malignant gliomas. J Neurooncol. 2013 Jun 8. [Epub ahead of print] PMID: 23748572

NEUROIMAGING Differentiation of glioblastomas from metastatic brain tumors

PROGNOSIS

Prognostic value of lysyl oxidase (LOX) genetic variants Polymorphism in the LOX gene was associated with increased susceptibility to glioma. LOX is a copper-dependent amine oxidase that plays important roles in the development and homeostasis of primary brain tumors. In the Chinese population individuals who carried the 473A allele had a 1.44-fold of increased risk for glioma compared to those with the 473G allele . The authors suggested that polymorphism in the LOX gene could be used as prognostic factor for glioma.
Han S, Feng S, Yuan G, Dong T, Gao D, Liang G, Wei X. Lysyl oxidase genetic variants and the prognosis of glioma. APMIS. 2013 Jun 12. doi: 10.1111/apm.12133. [Epub ahead of print] PMID:23758270

[11C]methyl-l-tryptophan (AMT)-positron emission tomography (PET) can enhance pretreatment differentiation of newly diagnosed glioblastomas from brain metastases with > 90% accuracy.
Kamson DO, Mittal S, Buth A, Muzik O, Kupsky WJ, Robinette NL, Barger GR, Juhsz C. Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison. Mol Imaging. 2013 Aug 1;12(5):327-37.

EXPERIMENTAL PHARMACOLOGY Gefitinib selectively inhibits tumor cell migration in EGFRamplified human glioblastoma (GBM)

Prognostic factors in adult hemispheric World Health Organization Grade II gliomas (GIIGs)

Spontaneous prognostic factors (tumor size, location, neurological symptoms and status and patient age) have the greatest influence on the survival expectancy of adults harboring GIIGs.

Gefitinib Structure

__________________________________________________________________________________________________________________________ Volume 1 (3), June 2013. www.gliomas.org

GLIOMAS.ORG NEWSLETTERS II Anticancer Drugs

By an optimized ex vivo organotypic slice culture system that allows the labeling and tracking of tumor cells in human GBM slice cultures researcher found that EGFR amplification was correlated with increased migration speed and efficiency compared with nonamplified tumors. Gefitinib resulted in a selective and significant reduction of tumor cell migration in EGFRamplified tumors.
Parker JJ, Dionne KR, Massarwa R, Klaassen M, Foreman NK, Niswander L, Canoll P, Kleinschmidt-Demasters BK, Waziri A. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma. Neuro Oncol. 2013 Jun 7. [Epub ahead of print] PMID: 23749785 EPIDEMIOLOGY Subsequent brain tumors in patients with autoimmune disease

Meeting 22-23 August, 2013 Stockholm, Sweden

Confirmed Speakers from

US Germany France UK Sweden Egypt Australia Israel Japan Saudi Arabia Mexico Russia

A study showed that none of the 33 autoimmune diseases (AIs) influenced the risk of glioma. However, many AIds negatively influence survival in glioma and meningioma, probably through added physical burden or therapeutic limitations. This study highlights the need for Information of an existing AId in patients with newly diagnosed brain tumors in order to with the prognostic assessment and the design of treatment.
Hemminki K, Liu X, Frsti A, Ji J, Sundquist J, Sundquist K. Subsequent brain tumors in patients with autoimmune disease. Neuro Oncol. 2013 Jun 11. [Epub ahead of print] PMID: 23757294

and other countries will present their work

www.anticancerdrugs.org/2013

NEWS Glioblastoma Patients Treated With Bevacizumab May Experience Reduced Cognitive Function and Quality of Life

Results from the large national multi-center Phase III trial, RTOG 0825 presented at the annual meeting of the American Society of Clinical Oncology (ASCO) suggest that many glioblastoma patients treated with bevacizumab (Avastin) have significant deterioration in neurocognitive function, symptoms and quality of life. The changes often predict treatment outcomes. Bevacizumav does not offer benefit to newly diagnosed glioblastoma compared to placebo.
Source: http://www.mdanderson.org/newsroom/newsreleases/2013/bevacizumab-offers-no-benefit.html

www.gliomas.org/shop

_____________________________________________________________________________________________________________________________ Volume 1 (3), June 2013. www.gliomas.org